{"id":46464,"date":"2022-07-22T03:02:01","date_gmt":"2022-07-22T01:02:01","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\/"},"modified":"2022-07-22T03:02:01","modified_gmt":"2022-07-22T01:02:01","slug":"innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\/","title":{"rendered":"InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City\u2019s Early Access Program"},"content":{"rendered":"
\n

BEIJING–(BUSINESS WIRE)–InnoCare (HKEX: 09969) today announced that tafasitamab (Minjuvi\u00ae<\/sup>) in combination with lenalidomide has been approved by the Health Commission and Medical Products Administration of Hainan Province, under the early access program in Boao Lecheng International Medical Tourism Pilot Zone, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). Through this program, the first prescription of tafasitamab in combination with lenalidomide was filled in China at the Ruijin Hainan Hospital for an eligible DLBCL patient.\n<\/p>\n

\nBoao Lecheng International Medical Tourism Pilot Zone, also known as Boao Hope City, allows individuals with urgent unmet needs to access innovative drugs, medical devices and technologies that have not yet been approved by NMPA in China but that have been approved by regulatory authorities overseas.\n<\/p>\n

\nDr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, \u201cThis prescription marks the first application of tafasitamab for patients in China. InnoCare has been committed to bringing innovative drugs to patients and physicians in China. In addition to Hainan practice, as previously announced, we are advancing the registrational trial recently approved by the NMPA with the goal of providing relapsed or refractory diffuse large B-cell lymphoma patients with unmet medical needs access to this combination, if approved.\u201d\n<\/p>\n

\nTafasitamab, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, is not approved by the NMPA for any indication in China, except for the early access program in Boao Lecheng International Medical Tourism Pilot Zone for the treatment of eligible DLBCL patients.\n<\/p>\n

\nTafasitamab is conditionally approved by both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) in combination with lenalidomide for the treatment of relapsed or refractory DLBCL patients who are not eligible for ASCT.\n<\/p>\n

\nDLBCL is the most common type of non-Hodgkin lymphoma (NHL), and its incidence accounts for 31% to 34% of NHL globally. In China, DLBCL accounts for 45.8% of all NHLs1<\/sup>.\n<\/p>\n

\nAbout tafasitamab<\/b>\n<\/p>\n

\nTafasitamab is a humanized Fc-modified CD19 targeting immunotherapy.\n<\/p>\n

\nIn 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc.\n<\/p>\n

\nTafasitamab incorporates an XmAb\u00ae<\/sup> engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).\n<\/p>\n

\nIn the United States, Monjuvi\u00ae<\/sup> (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for ASCT. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).\n<\/p>\n

\nIn Europe, Minjuvi\u00ae<\/sup> (tafasitamab) received conditional approval, in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).\n<\/p>\n

\nTafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in several ongoing combination trials.\n<\/p>\n

\nMonjuvi\u00ae<\/sup> and Minjuvi\u00ae<\/sup> are registered trademarks of MorphoSys AG. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name MONJUVI\u00ae<\/sup> in the U.S., and marketed by Incyte under the brand name Minjuvi\u00ae<\/sup> in Europe, the UK and Canada. As part of its agreement with MorphoSys, Incyte received exclusive commercialization rights for tafasitamab outside the United States, and in August 2021, Incyte entered into a collaboration and license agreement with InnoCare for the development and exclusive commercialization of tafasitamab in hematology and oncology in Greater China.\n<\/p>\n

\nXmAb\u00ae<\/sup> is a registered trademark of Xencor, Inc.\n<\/p>\n

\nAbout InnoCare
\n
<\/b>InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and\/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou and the United States.\n<\/p>\n

\nInnoCare Forward-looking Statements
\n
<\/b>This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management’s intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.\n<\/p>\n

\n1<\/sup> \u4e2d\u534e\u533b\u5b66\u4f1a\u8840\u6db2\u5b66\u5206\u4f1aHematology Branch of Chinese Medical Association\uff082013\uff09\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia<\/b>
Chunhua Lu
\n
86+10-66609879
\n
chunhua.lu@innocarepharma.com<\/a><\/p>\n

Investors<\/b>
86+10-66609999
\n
ir@Innocarepharma.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BEIJING–(BUSINESS WIRE)–InnoCare (HKEX: 09969) today announced that tafasitamab (Minjuvi\u00ae) in combination with lenalidomide has been approved by the Health Commission and Medical Products Administration of Hainan Province, under the early access program in Boao Lecheng International Medical Tourism Pilot Zone, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46464","6":"format-standard","7":"category-industry"},"yoast_head":"\nInnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City\u2019s Early Access Program - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City\u2019s Early Access Program - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BEIJING–(BUSINESS WIRE)–InnoCare (HKEX: 09969) today announced that tafasitamab (Minjuvi\u00ae) in combination with lenalidomide has been approved by the Health Commission and Medical Products Administration of Hainan Province, under the early access program in Boao Lecheng International Medical Tourism Pilot Zone, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-22T01:02:01+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City\u2019s Early Access Program\",\"datePublished\":\"2022-07-22T01:02:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\\\/\"},\"wordCount\":828,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\\\/\",\"name\":\"InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City\u2019s Early Access Program - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-07-22T01:02:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City\u2019s Early Access Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City\u2019s Early Access Program - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\/","og_locale":"en_US","og_type":"article","og_title":"InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City\u2019s Early Access Program - Pharma Trend","og_description":"BEIJING–(BUSINESS WIRE)–InnoCare (HKEX: 09969) today announced that tafasitamab (Minjuvi\u00ae) in combination with lenalidomide has been approved by the Health Commission and Medical Products Administration of Hainan Province, under the early access program in Boao Lecheng International Medical Tourism Pilot Zone, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-22T01:02:01+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City\u2019s Early Access Program","datePublished":"2022-07-22T01:02:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\/"},"wordCount":828,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\/","url":"https:\/\/pharma-trend.com\/en\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\/","name":"InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City\u2019s Early Access Program - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-07-22T01:02:01+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City\u2019s Early Access Program"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46464"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46464\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}